This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Moon, C. Articles by Roth, J. A. Search for Related Content PubMed PubMed Citation Articles by Moon, C. Articles by Roth, J. A. Related Collections Clinical Research Clinical Research: Clinical Trials

Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer

Departments of Thoracic/Head and Neck Medical Oncology [Y. O.] and Thoracic and Cardiovascular Surgery [J. A. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Department of Otolaryngology and Oncology, The Johns Hopkins School of Medicine and The Sidney Kimmel Cancer Center, Baltimore, Maryland 21205 [C. M.]

Targeting the specific genetic lesions responsible for carcinogenesis and cancer progression is an attractive strategy for developing more effective anticancer therapeutics and reducing treatment-related toxicity. The restoration of defective tumor suppressor gene pathways by replacement of tumor suppressor genes in cancer cells has been studied in lung cancer and head and neck cancer (HNC). The most extensively studied agent is the wild-type p53 tumor suppressor gene delivered by an adenoviral vector. Clinical trials to date in non-small cell lung cancer and HNC have consistently shown evidence of gene transduction and expression, mediation of apoptosis, and clinical responses including pathological complete responses. It is also clear, however, that this approach can be improved further. Promising avenues for investigation include improved gene delivery systems, induction of bystander effects, design of immunogene and antiangiogenesis gene therapies, and adjuvant use of gene therapy with conventional chemotherapy, radiation therapy, and surgery. These strategies, however, will need further refinement to succeed clinically. This review examines several important issues in cancer gene therapy in general and the most recent achievements in gene therapy for HNC and non-small cell lung cancer.